Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
Cost of Revenue
Verona Pharma PLC
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cost of Revenue
-$2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cost of Revenue
-£8.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cost of Revenue
-$9.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-5%
|
|
|
Indivior PLC
LSE:INDV
|
Cost of Revenue
-$175m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cost of Revenue
-$1.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cost of Revenue
-£69.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-14%
|
|
Verona Pharma PLC
Glance View
Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.
See Also
What is Verona Pharma PLC's Cost of Revenue?
Cost of Revenue
-2.6m
USD
Based on the financial report for Dec 31, 2024, Verona Pharma PLC's Cost of Revenue amounts to -2.6m USD.
You don't have any saved screeners yet